Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2012

View Archived Issues

Bionomics patents novel acetylcholine receptor modulators

Centaurus BioPharma divulges novel GPR119 receptor agonist

Dual-action AT1 receptor antagonist/PPAR-gamma agonist selected as clinical candidate

Pacific Therapeutics advances first-in-human trial of repurposed combination

Transgenomic receives NIH grant for cancer diagnostic

Scientists in Germany identify new resistance loci for severe malaria

Enrollment and dosing begin in first-in-human AT-001 trial

Bayer kicks off phase III program for ciprofloxacin DPI

Amgen products target free fatty acid FFA1 receptor for diabetes

New BACE inhibitor reduces CNS beta-amyloid in vivo

NIH-sponsored study to evaluate low-dose methotrexate's potential to reduce cardiovascular events

New PDE2A/10A inhibitors reported

Investigators extract new HMG-CoA reductase inhibitors from yeast

Sato Pharmaceutical designs new urate anion exchanger inhibitors

New antifungals designed in Japan

Research at U.S. university yields new MAT 2 inhibitors

New SPT inhibitor selected for further development in hepatitis C

Janssen launches phase III rheumatoid arthritis program

PCI Biotech selects next indication for Amphinex

MediciNova reports encouraging preliminary phase Ib results on bedoradrine

Once-daily tablets approved in Japan for use in ulcerative colitis in remission

Growject approved for fourth indication in Japan

AcelRx kicks off new trial of Sufentanil NanoTabs

Recordati completes acquisition

Microbix and Zydus Cadila sign agreement for Kinlytic

Synergy Pharmaceuticals to acquire nucleoside analogue from Bristol-Myers Squibb

First angiotensin AT1 receptor antagonist approved for pediatric use in Japan

Northwest Bio gains MHRA clearance for DCVax-L trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...